Transition clinic attendance is associated with improved beliefs and attitudes toward medicine in patients with inflammatory bowel disease

Table 1 Demographics

	Transition	Control	P value
	n (%) ormean ± SD	n (%) ormean ± SD
Gender
Female	23 (40.4)	31 (56.4)	0.13
Diagnosis
CD	47 (79.7)	34 (64.2)	0.07
UC/IBDU	12 (20.3)	19 (35.8)
Age (yr)
At diagnosis	13.0 ± 2.9	13.0 ± 3.8	0.87
Current	19.7 ± 1.3	20.6 ± 1.2	0.0012
Disease duration (yr)	6.9 ± 3.2	7.6 ± 3.9	0.30
Prior GI surgery	13 (22.0)	12 (21.8)	0.98
Medication1
5-ASA	14 (25.0)	20 (37.0)	0.24
IM	17 (30.4)	12 (22.2)	0.33
Anti-TNF	6 (10.7)	6 (11.1)	1.00
Combination	13 (23.2)	5 (9.3)	0.07
Any	43 (76.8)	37 (68.5)	0.33
Regular blood work	45 (80.4)	30 (55.6)	0.012

¹Subgroups in medication row denote patients receiving oral 5-ASA products, IM only, anti-TNF only, combination therapy (IM and anti-TNF) only, or any IBD medication;

²Statistically significant. 5-ASA: 5-aminosalicylic acid; anti-TNF: Anti-tumour necrosis factor agents including infliximab and adalimumab; CD: Crohn’s disease; IBDU: Inflammatory bowel disease unspecified; IM: Immunomodulators including methotrexate, 6-mercaptopurine, and azathioprine; UC: Ulcerative colitis.